Author and publication year | Design | Malignancies | Number of patients | Number of patients with Bidirectional treatment | Gender (male/female) | Age, years (range or SD) | Previous tumor related surgery | Previous systemic chemotherapy | |
---|---|---|---|---|---|---|---|---|---|
Alyami et al. 2017 [27] | Retrospective | Total | 73 | 64 | Total: | 31/42 | 57.1 (32.3-77.9)d | NR | 64 |
- Gastric | 26 | NR | Bidirectional: | NR | NR | NR | NR | ||
- Colon | 20 | NR | |||||||
- Ovarian | 13 | NR | |||||||
- Mesothelioma | 8 | NR | |||||||
- Pseudomyxoma | 1 | NR | |||||||
- Others | 5 | NR | |||||||
Demtröder et al. 2015 [28] | Retrospective | Colorectal | 17 | 11 | Total: | 10/7 | 59 (+/-12)e | 17 | 16 |
Bidirectional: | NR | NR | 11 | 10 | |||||
Falkenstein et al. 2018 [29] | Retrospective | Biliary tract | 13 | 3 | Total: | 8/5 | 58 (37-75)f | 9 | 7 |
Bidirectional: | NR | NR | NR | NR | |||||
Graversen et al. 2017 [30] | Prospective | Pancreatic | 5 | 1 | Total: | 3/2 | 62 (49-69)g | 2 | 5 |
Bidirectional: | 0/1 | 62 | 0 | 1 | |||||
Hilal et al. 2017 [31] | Retrospective | Total (all gynecological) | 84 | 6 | Total: | 0/84 | 60.4 (+/-12.2)e | 84i | 84 |
- Ovarian | 77 | NR | Bidirectional: | 0/6 | NR | 6i | 6 | ||
- Fallopian tube | 2 | NR | |||||||
- Peritoneal | 5 | NR | |||||||
Khomyakov et al. 2016 [24] | Prospective | Gastric | 31 | 31 | Total: | 9/22 | 52 (25-70)f | NR | 7 |
Bidirectional: | 9/22 | 52 (25-70)f | NR | 7 | |||||
Khosrawipour et al. 2017 [32] | Retrospective | Pancreatic | 20 | 6 | Total: | 15/5 | 64.9 (45-87)g | 8 | 20 |
Bidirectional: | 5/1 | 67.5 (52-75)g | 3 | 6 | |||||
Nadiradze et al. 2015 [33] | Retrospective | Gastric | 24 | 8 | Total: | 12/12 | 56 (+/-13)e | 14 | 19 |
Bidirectional: | NR | NR | NR | NR | |||||
Reymond et al. 2016 [34]a | Retrospective | Total | 3 | 1b | Total: | 1/2 | 68 (59-72)g | 2 | 3 |
- CUP | 1 | 0 | Bidirectional: | 0/1 | 59 | 1 | 1 | ||
- Pancreatic | 1 | 0 | |||||||
- Gallbladder | 1 | 1 | |||||||
Robella et al. 2016 [26] | Retrospective | Total | 14 | 13 | Total: | NRc | 52.5 (39-78)g | 9 | 14 |
- Mesothelioma | 2 | 1 | Bidirectional: | NRc | 52 (39-78)g | 8 | 13 | ||
- Ovarian | 3 | 3 | |||||||
- Colorectal | 2 | 2 | |||||||
- Pseudomyxoma | 1 | 1 | |||||||
- Gastric | 6 | 6 | |||||||
Farinha et al. 2017 [35] | Retrospective | Total | 42 | 1 | Total: | 8/34 | 66 (59-73)h | NR | NR |
- Gynecological | 21 | NR | Bidirectional: | NR | NR | NR | NR | ||
- CRC | 14 | NR | |||||||
- Gastric | 3 | NR | |||||||
- Small bowel | 1 | NR | |||||||
- Appendix | 1 | NR | |||||||
- Pseudomyxoma | 1 | NR | |||||||
- Mesothelioma | 1 | NR | |||||||
Hübner et al. 2017 [36] | Retrospective | Total | 60 | NR | Total: | NR | NR | NR | NR |
- Gynecological | NR | NR | Bidirectional: | NR | NR | NR | NR | ||
- Digestive | NR | NR |